---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-212064"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:58:48.244885+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study

## Summary
- Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.
- Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.
- FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.
- Received $6.7M net proceeds from January 2026 warrant inducement.
- Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference.

## SEC filing metadata
- accession: 0001193125-26-212064
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/0001193125-26-212064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/revb-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-212064
- JSON: https://secwatch.observer/filing/0001193125-26-212064.json
- Plain text: https://secwatch.observer/filing/0001193125-26-212064.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2026 results: net income $3.0 million, or $2.71 basic and diluted net loss per share.
  - Period: three months ended March 31, 2026
  - Net income: $3.0 million, or $2.71 basic and diluted net loss per share
  - Result: reported results
  source text: 31, 2026 was $3.2 million compared to net cash used for operating activities of $2.8 million for the same period in 2025. Net loss for the three months ended March 31, 2026 was $3.0 million, or $2.71 basic and diluted net loss per share compared to net loss of $2.1 million, or $25.34 basic and diluted net loss per share for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/0001193125-26-212064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.